Abbott ABT Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net Sales by Business | |||||
| Diagnostic Products | $8.94B-4.3% | $9.34B-6.5% | $9.99B-39.4% | $16.47B+6.1% | |
| Established Pharmaceuticals | $5.54B+6.6% | $5.19B+2.5% | $5.07B+3.1% | $4.91B+4.1% | |
| Medical Devices | $21.39B+12.6% | $18.99B+12.4% | $16.89B+14.1% | $14.8B+2.2% | |
| Nutritional Products | $8.45B+0.5% | $8.41B+3.2% | $8.15B+9.3% | $7.46B-10.1% | |
| Net Sales by Geography | |||||
| All Other Countries | $15.98B+8.1% | $14.79B+4.4% | $14.17B-5.6% | $15.01B-4.6% | |
| China | $1.91B-9.7% | $2.11B-6.2% | $2.25B+5.6% | $2.13B-10.8% | |
| Germany | $2.76B+8.7% | $2.54B+8.3% | $2.35B+0.2% | $2.34B-9.0% | |
| India | $1.87B+3.0% | $1.82B+3.8% | $1.75B+6.1% | $1.65B+5.6% | |
| International | $27.2B+6.1% | $25.63B+3.9% | $24.66B-3.3% | $25.51B-3.5% | |
| Japan | $1.48B+2.4% | $1.44B-4.8% | $1.51B-21.7% | $1.93B+14.0% | |
| Switzerland | $1.87B+7.1% | $1.75B+6.7% | $1.64B+22.6% | $1.34B+1.8% | |
| United Kingdom | $1.34B+13.1% | $1.19B+19.6% | $991M— | —— | |
| United States | $17.13B+4.9% | $16.32B+5.6% | $15.45B-14.8% | $18.14B+9.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Abbott break its business down?
- Abbott (ABT) reports net sales by business across 4 parts — Diagnostic Products, Established Pharmaceuticals, Medical Devices and Nutritional Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Abbott's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Abbott's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
